Buy Adzynma (apadamtase alfa; cinaxadamtase alfa)

What is Adzynma (ADAMTS13, recombinant-krhn) for?

Adzynma (ADAMTS13, recombinant-krhn) is a lab-made version of the human enzyme ADAMTS13. It is indicated for the treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). Adzynma (ADAMTS13, recombinant-krhn) can be used as prophylactic or on-demand therapy ^[1].

Adzynma (ADAMTS13, recombinant-krhn) is administered as an intravenous injection. It’s available as a lyophilized powder for reconstitution, in single-dose vials containing 500 or 1500 international units ^[1].

How does Adzynma (ADAMTS13, recombinant-krhn) work?

Adzynma (ADAMTS13, recombinant-krhn) is a synthetic variant of a natural enzyme called ADAMTS13. This enzyme controls the activity of a substance in our blood, called von Willebrand factor (VWF). While VWF is essential for clotting, it can occasionally lead to the formation of tiny, potentially hazardous blood clots. ADAMTS13 breaks down large VWF clusters into smaller pieces, thus reducing the chance of these small, unwanted clots forming ^[1].

Where has Adzynma (ADAMTS13, recombinant-krhn) been approved?

Adzynma (ADAMTS13, recombinant-krhn) is approved by the FDA in the USA ^[2].

References:

1. Package Insert and Patient Information – ADZYNMA. FDA, Accessed 21 November 2023.
2. FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder. FDA, 9 November